The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1503713
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 22 articles
Machine Learning Models for Coagulation Dysfunction Risk in Inpatients Administered β-Lactam Antibiotics
Provisionally accepted- 1 The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China
- 2 Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Beijing, China
The β-Lactam antibiotics represent a widely used class of antibiotics, yet the latent and often overlooked risk of coagulation dysfunction associated with their use underscores the need for proactive assessment. Machine learning methodologies can offer valuable insights into evaluating the risk of coagulation dysfunction associated with β-lactam antibiotics. This study aims to identify the risk factors associated with coagulation dysfunction related to β-lactam antibiotics and to develop machine learning models for estimating the risk of coagulation dysfunction with real-world data. A retrospective study was performed using machine learning modeling analysis on electronic health record data, employing five distinct machine learning methods. The study focused on adult inpatients discharged from January 1, 2018, to December 31, 2021, at the First Affiliated Hospital of Shandong First Medical University. The models were developed for estimating the risk of coagulation dysfunction associated with various β-lactam antibiotics based on electronic health record feasibility. The dataset was divided into training and test sets to assess model performance using metrics such as total accuracy and area under the curve. The study encompassed risk-factor analysis and machine learning model development for coagulation dysfunction in inpatients administered different β-lactam antibiotics. A total of 45,179 participants were included in the study. The incidence of coagulation disorders related to cefazolin sodium, cefoperazone/sulbactam sodium, cefminol sodium, amoxicillin/sulbactam sodium, and piperacillin/tazobactam sodium was 2.4%, 5.4%, 1.5%, 5.5%, and 4.8%, respectively.Machine learning models for estimating coagulation dysfunction associated with each β-lactam antibiotic underwent validation with 5-fold cross-validation and test sets. On the test set, the optimal models for cefazolin sodium, cefoperazone/sulbactam sodium, cefminol sodium, amoxicillin/sulbactam sodium, and piperacillin/tazobactam sodium yielded AUC values of 0.798, 0.768, 0.919, 0.783, and 0.867, respectively. The study findings suggest that machine learning classifiers can serve as valuable tools for identifying patients at risk of coagulation dysfunction associated with β-lactam antibiotics and intervening based on high-risk predictions. Enhanced access to administrative and clinical data could further enhance the predictive performance of machine learning models, thereby expanding pharmacovigilance efforts.
Keywords: β-Lactam antibiotics, Coagulation disorders, Risk factors, machine learning, Pharmacovigilance
Received: 29 Sep 2024; Accepted: 11 Nov 2024.
Copyright: © 2024 Hua, Li, Lao, Chen, Ma and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiao Li, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.